The digital health company Noom announced Thursday that it is expanding its weight-loss drug offerings to include pills, ...
A $29 entry price helps provide accessibility for people pursuing weight loss goalsService includes all features of Noom Med ...
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...
People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
The global Oral Anti-Diabetic Drug market is poised for substantial growth, driven by increasing diabetes cases, advancements ...
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback